Centene Corporation: Q2 2024 Financial Summary
Business Context and Reporting Period
This summary covers Centene Corporation's (CNC) Form 10-Q for the quarterly period ended June 30, 2024. Centene is a leading provider of government-sponsored healthcare, serving over 28 million members through Medicaid, Medicare, and Commercial Marketplace programs. The reporting period reflects the ongoing impact of Medicaid redeterminations following the end of the public health emergency, alongside strategic divestitures and growth in the Commercial segment.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenues | $39.84 billion | $37.61 billion | $80.24 billion | $76.50 billion |
| Premium & Service Revenues | $35.97 billion | $34.84 billion | $72.31 billion | $69.79 billion |
| Net Earnings (GAAP) | $1.15 billion | $1.06 billion | $2.31 billion | $2.19 billion |
| Diluted EPS (GAAP) | $2.16 | $1.92 | $4.32 | $3.96 |
| Adjusted Diluted EPS | $2.42 | $2.10 | $4.68 | $4.21 |
| Health Benefits Ratio (HBR) | 87.6% | 87.0% | 87.3% | 87.0% |
| SG&A Expense Ratio | 8.0% | 8.7% | 8.5% | 8.6% |
| Cash & Equivalents | $17.61 billion | $17.19 billion | $17.61 billion | $17.19 billion |
| Total Debt | $17.63 billion | $17.83 billion | $17.63 billion | $17.83 billion |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 6% year-over-year (Q2) and 5% year-over-year (YTD), driven by a 34% increase in Commercial Marketplace membership and favorable risk adjustment results, partially offset by lower Medicaid membership due to redeterminations.
- Profitability: Net earnings attributable to Centene rose 8% in Q2 and 6% YTD. Adjusted EPS increased 15% in Q2 and 11% YTD, reflecting operational efficiencies and divestiture gains.
- Segment Performance:
- Commercial: Revenues surged 49% (Q2) and 48% (YTD) due to Marketplace expansion and strong product design.
- Medicaid: Revenues declined 2% (Q2) and 2% (YTD) as membership decreased by 2.4 million since redeterminations began in April 2023. Gross margin compression occurred due to higher acuity post-redetermination.
- Medicare: Revenues increased 6% (Q2) and 3% (YTD), driven by a 47% jump in Prescription Drug Plan (PDP) membership, though Medicare Advantage revenue was impacted by lower Star ratings.
- Other: Revenues declined 22% (Q2) and 24% (YTD) primarily due to the divestiture of Circle Health and Operose Health.
- Divestitures: The company recorded gains related to the finalization of the Magellan Specialty Health divestiture ($83 million YTD) and the Circle Health divestiture ($20 million YTD).
Guidance, Outlook, and Risks
- Membership Outlook: Total managed care membership increased slightly to 28.5 million. Management anticipates remaining Medicaid membership reductions will be limited as most states have completed redetermination processes.
- Operational Drivers: Future results are expected to be influenced by the implementation of a new third-party PBM contract (commenced Jan 2024) and the resolution of third-party protests in the Medicaid segment.
- Capital Allocation: The company continues to execute a $10 billion stock repurchase program, with approximately $4.4 billion remaining as of June 30, 2024. They repurchased $800 million of stock in Q2.
- Risks and Contingencies:
- Regulatory: Ongoing uncertainty regarding Medicaid redeterminations, CMS Star ratings, and potential changes to federal healthcare programs.
- Legal: Routine legal proceedings, including compliance reviews and disputes regarding pharmacy benefits (Envolve Pharmacy Solutions), though reserves are not currently material.
- Investment Risk: A hypothetical 1% increase in interest rates could decrease the fair value of fixed-income investments by approximately $645 million.
Investor Verification Checklist
- Medicaid Redetermination Impact: Verify the extent of membership loss and the timeline for rate adjustments to match post-redetermination acuity.
- Medicare Star Ratings: Assess the long-term revenue impact of the 2024 Star rating decreases and the effectiveness of the $335 million premium deficiency reserve.
- Commercial Growth Sustainability: Evaluate the durability of the 34% Marketplace membership growth and the impact of risk adjustment settlements.
- Divestiture Proceeds: Confirm the finalization of working capital adjustments for Magellan and Circle Health to ensure no further earnings volatility.
- Debt Covenants: Monitor compliance with the maximum debt-to-EBITDA ratio (4.0 to 1.0) and fixed charge coverage ratio under the credit agreement.